As such, increasing pulmonary VEGF during lung development, particularly during a critical period of alveolarization, much of which occurs postnatally in humans, has become an attractive therapeutic target for developmental lung diseases including CDH-associated PH, bronchopulmonary dysplasia, and respiratory distress syndrome3,8–10. The gene discussed is VEGFA; the disease is congenital diaphragmatic hernia.